Chronic HBV infection is major problem in Asian countries. Years after chronic infection, in some cases serum HBsAg level declines to unmeasurable level. Some of patients develop anti-HBsAb but there is no standard treatment to accelerate HBsAg seroconversion. There is a study to determine efficacy and safety of HBV vaccine in who is Chronic HBV infection and lost their HBsAg without seroconversion to anti-HBsAb.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
97
Commercial Hepatitis B vaccine (Engerix B) 20 microgram subcutaneous injection at month 0, 1, 6
HBsAg, HBsAb test Ultrasound upper abdomen every 6 months
Faculty of Medicine Siriraj Hospital
Bangkoknoi, Bangkok, Thailand
RECRUITINGHBsAb level at 4 weeks after complete vaccine injection
HBsAb level more than 10 mIU/ml at 7 months
Time frame: an average of 7 months
HBsAb level at 6 months after complete vaccine injection
HBsAb level more than 10 mIU/ml at 6 months
Time frame: an average of 1 year
Adverse event from HBV vaccine
Any adverse event from HBV vaccine by CTCAE v4.0
Time frame: an average of 1 year
Factors associated with HBV vaccine response
Factors associated with HBV vaccine response at 12 months
Time frame: an average of 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.